Abstract
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: - To assess the long-term efficacy of dupilumab in pediatric participants with AD - To assess the trough concentrations of functional dupilumab in serum and the immunogenicity in pediatric participants with AD after re-treatment with dupilumab Optional Pre-filled Pen (PFP) Sub-Study in pediatric patients ≥2 to <12 years of age with ad co-primary objectives are: - to evaluate the pharmacokinetic (pk) of dupilumab pfps - to evaluate the safety of dupilumab pfps secondary objective is: - to evaluate the immunogenicity of dupilumab pfps>
